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Abstract
Background:  PTTG-1 (pituitary tumor transforming gene) is a novel oncogene that is
overexpressed in tumors, such as pituitary adenoma, breast and gastrointestinal cancers as well as
in leukemia. In this study, we examined the role of PTTG-1 expression in lung cancer with regard
to histological subtype, the correlation of PTTG-1 to clinical parameters and relation on patients'
survival.
Methods:  Expression of PTTG-1 was examined immunohistochemically on formalin-fixed,
paraffin-embedded tissue sections of 136 patients with small cell lung cancer (SCLC) and 91
patients with non-small cell lung cancer (NSCLC), retrospectively. The intensity of PTTG-1
expression as well as the proportion of PTTG-1 positive cells within a tumor was used for
univariate and multivariate analysis.
Results: PTTG-1 expression was observed in 64% of SCLC tumors and in 97.8% of NSCLC
tumors. In patients with SCLC, negative or low PTTG-1 expression was associated with a shorter
mean survival time compared with patients with strong PTTG-1 expression (265 ± 18 days vs. 379
± 66 days; p = 0.0291). Using the Cox regression model for multivariate analysis, PTTG-1
expression was a significant predictor for survival next to performance status, tumor stage, LDH
and hemoglobin.
In contrast, in patients with NSCLC an inverse correlation between survival and PTTG-1
expression was seen. Strong PTTG-1 expression was associated with a shorter mean survival of
306 ± 58 days compared with 463 ± 55 days for those patients with no or low PTTG-1 intensities
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(p = 0.0386). Further, PTTG-1 expression was associated with a more aggressive NSCLC
phenotype with an advanced pathological stage, extensive lymph node metastases, distant
metastases and increased LDH level. Multivariate analysis using Cox regression confirmed the
prognostic relevance of PTTG-1 expression next to performance status and tumor stage in patients
with NSCLC.
Conclusion: Lung cancers belong to the group of tumors expressing PTTG-1. Dependent on the
histological subtype of lung cancer, PTTG-1 expression was associated with a better outcome in
patients with SCLC and a rather unfavourable outcome for patients with NSCLCs. These results
may reflect the varying role of PTTG-1 in the pathophysiology of the different histological subtypes
of lung cancer.
Introduction
Progress of cancer research on molecular level led to the
discovery and a better understanding of genes involved in
the development of tumor growth. In 1997, a new proto-
oncogene was identified in pituitary growth hormone
secreting tumor cells leading to a more malignant pheno-
type [1]. As a result, it was termed pituitary tumor-trans-
formation gene (PTTG-1). The 23 kDa PTTG-1 protein
consists of 202 amino acids and is located on chromo-
some 5q33, a locus previously associated with progres-
sion of lung cancer [2-4]. PTTG-1 is physiologically
expressed in normal tissues of different organs such as tes-
tis, colon and lung while an overexpression was observed
in several malignant tumors and cancer cell lines, includ-
ing carcinomas of the gastrointestinal tract, breast, lung,
as well as in leukemia and lymphoma [5-8]. The possible
role of PTTG-1 as a proto-oncogene in vivo was exempli-
fied when NIH 3T3 fibroblasts were transfected with the
full-length coding sequence of PTTG-1. The transfection
of PTTG-1 lead to morphological changes, alterations in
growth characteristics of the fibroblasts and tumor forma-
tion resulted when injected into nude mice. Irrespective of
the compelling evidence that PTTG-1 is a novel oncogene,
the mechanisms underlying the induction of malignant
cell transformation are not understood. Some reports sug-
gest that PTTG-1 plays a role in the regulation of transcrip-
tion [9,10] such as induction of basic fibroblast growth
factor [11] or activation of c-Myc [12] leading to increased
angiogenesis as well as cell proliferation. PTTG-1 might
also be related to cell cycle genes and the induction of
apoptosis depending on the particular type of cell [12-14].
In the present study, we examined the prognostic value of
PTTG-1 expression for survival in relationship to the dif-
ferent histological subtypes of lung cancer. The intensity
of PTTG-1 staining as well as the proportion of PTTG-1
positive cells within a tumor was taken into consideration
for univariate and multivariate survival analyses.
Patients and methods
Characteristics of the patients with SCLC and NSCLC
Formalin-fixed, paraffin-embedded tissue sections from
136 patients with primary SCLC and 91 patients with pri-
mary NSCLC were used for immunohistochemical detec-
tion of PTTG-1. Specimens were obtained from the
Institute of Pathology of the University of Duesseldorf.
Biopsies from primary lung tumor were taken at initial
clinical presentation. The original diagnosis of SCLC or
NSCLC was confirmed by two different pathologists
before the biopsy was accepted for this study. The his-
topathological diagnosis was based on HE stains in each
cases and confirmed by immunohistochemical staining of
cytokeratin 5 and 7, chromogranin A, synaptophysin and
TTF-1. 91 NSCLC tumors were classified into histological
subtypes: 55 adenocarcinomas (60.4%), 28 squamous
cell carcinomas (30.8%), six large cell carcinomas (6.6%)
and two adeno-squamous cell carcinomas (2.2%). The
patients enrolled in the study were patients from the Uni-
versity of Duesseldorf and associated academic hospitals
of the University of Duesseldorf between 1983 and 2003.
Clinical data of the patients were collected from chart
review with given approval from the ethics committee of
the University of Duesseldorf. Baseline characteristics of
chosen patients are presented in Table 1 and 2. Survival
time in days was calculated from the date of histopatho-
logical diagnosis. Performance status of the patients was
evaluated by applying standard WHO criteria. All tumors
were classified according the current TNM system [15].
The stages I- IV were based on the revised version of the
International System for Staging Lung Cancer [16]. Chem-
otherapy was perfomed as a first-line treatment with an
average of 3.5 cycles (median: 3 ± 1.9 cycles; range: 1–12)
and 3.1 cyles (median: 3 ± 2.1 cycles; range: 1–11) in all
SCLC patients and 93.4% of NSCLC patients, respectively.
After recurrence of the tumor following surgical resection,
the remaining 6.6% patients with NSLCL were treated
with palliative chemotherapy.
The preferred chemotherapeutic regiment for 71.5% of
SCLC patients was a combination of cyclophosphamid
(1000 mg/m2 d1), epirubicin (65 mg/m2 d1) or adriamy-Journal of Carcinogenesis 2006, 5:4 http://www.carcinogenesis.com/content/5/1/4
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cin (45 mg/m2) and etoposid (120 mg/m2). A platinum-
based combination with cisplatin (90 mg/m2) or carbopl-
atin (300 mg/m2) and etoposid (150 mg/m2) was given in
18%, whereas other combinations were given in 10.5% of
patients.
For 70.3% of NSCLC patients the preferred chemothera-
peutic regiment was a platinum based combination (cis-
platin 75 mg/m2 or carboplatin AUC 5). In detail, 26.4%
of patients received a combination of platin and etoposid
(100 mg/m2); 19.7% of patients had a therapy based on
platin and paclitaxel (175 mg/m2) and 14.3% of patients
were treated with platin and vinorelbine (30 mg/m2).
Finally, 9.9% of patients had a cisplatin monotherapy
supported by radiotherapy. 12.1% of patients received a
combination of gemcitabine (1000 mg/m2) and vinorel-
bine (30 mg/m2). Other chemotherapeutic combinations
were given in 17.6% of cases.
Immunohistochemistry
As previously described by Saez et al. [17], a standardized
immunohistochemical staining procedure was adhered to
PTTG-1 detection, using a primary polyclonal antibody
against PTTG-1 (U.S. Biological, Massachusetts, USA).
Briefly, fresh tumor tissue specimens were immediately
formalin-fixed following bronchoscopy or computertom-
ographic-supported thoracal puncture. Samples were par-
affin-embedded, cut in 2- to 4 µm sections on poly-L-
lysine-coated slides. Following deparaffinization with
xylene (15 minutes), sections were rehydrated through
decreasing concentrations of ethanol (100%, 96% and
70%) and washed for 5 minutes. For antigen retrieval, the
specimens were heated in citrate buffer (pH 6) using a
pressure cooker for 15 minutes. Endogenous peroxidase
activity was eliminated by incubation with 3% hydrogen
peroxide for 15 minutes and unspecific binding of biotin
and avidin was blocked using a blocking solution (Dako,
Hamburg, Germany) for 15 minutes each slide. After
intensive washing for 5 minutes, slides were incubated
with 1% bovine serum albumin (Sigma, St.Louis, MO) to
block unspecific binding of the primary antibody.
The anti-PTTG-1 antibody (U.S. Biological, Massachu-
setts, USA) was diluted 1:100, and slides were incubated
with anti-PTTG-1 antibody for 1 hour. After washing, a
streptavidin horseradish peroxidase detection kit (DAKO,
Hamburg, Germany) containing 3,3'-diaminobenzidine
solution as substrate was used for immunohistochemical
staining according to the manufacturer's instructions.
Appropriate positive controls (testis and colon tumor tis-
sue) and appropriate negative control (kidney) were addi-
tionally evaluated in each run. All slides were
simultaneously assessed by two investigators (N.R. and
A.A.) using a double-headed discussion microscope. In a
final control process all slides were reviewed and the
results were confirmed by a third investigator (H.G.). The
staining intensities for PTTG-1 were evaluated semiquan-
titatively and classified into three groups. The first group
Table 2: Baseline characteristics of patients with NSCLC (N = 
91)
Patients (%)
Mean age (years) 62.6 ± 10.9 (range:31.5–87.8)
Sex
Male 67 (73.6%)
Female 24 (26.4%)
Smoking status
Smoker/former smoker 84 (92.3%)
Nonsmoker 5 (5.5%)
Not evaluable 2 (2.2%)
WHO performance status
03 4  ( 3 7 . 4 % )
I4 5  ( 4 9 . 4 % )
II 10 (11.0%)
Not evaluable 2 (2.2%)
Stage
Ia,b 3 (3.3%)
IIa,b 4 (4.4%)
IIIa,b 27 (29.7%)
IV 57 (62.6%)
LDH (units/L) 229.7 ± 142.1
Hemoglobin (g/dl) 13.4 ± 1.7
Thrombocytes (µl) 320736.3 ± 178681.1
Leukocytes (µl) 10319.8 ± 4925.3
Table 1: Baseline characteristics of patients with SCLC (N = 
136)
Patients (%)
Mean age (years) 60.8 ± 9.5 (range: 42.2–82.2)
Sex
Male 103 (75.7%)
Female 33 (24.3%)
Smoking status
Smoker/former smoker 120 (88.2%)
Nonsmoker 6 (4.4%)
Not evaluable 10 (7.4%)
WHO performance status
04 8  ( 3 5 . 3 % )
I6 1  ( 4 4 . 9 % )
II 18 (13.2%)
III 2 (1.5%)
Not evaluable 7 (5.1%)
Stage
Ia,b 1 (0.7%)
IIa,b 7 (5.1%)
IIIa,b 43 (31.6%)
IV 82 (60.3%)
Not evaluable 3 (2.2%)
LDH (units/L) 333.2 ± 233.3
Hemoglobin (g/dl) 13.4 ± 1.7
Thrombocytes (µl) 322416.7 ± 114639.9
Leukocytes (µl) 9208.9 ± 3017.9Journal of Carcinogenesis 2006, 5:4 http://www.carcinogenesis.com/content/5/1/4
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showed equal or stronger cytoplasmic staining intensity
compared with positive control. The second group
showed lower staining intensity of PTTG-1 compared with
the positive control. The third group showed no immuno-
histochemical evidence of PTTG-1 expression. For the esti-
mation, all tumor areas of one to four biopsies from
bronchoscopy were included. Generally, the staining
intensity and the proportion of PTTG-1 positive cells were
Immunohistochemical staining of PTTG-1 Figure 1
Immunohistochemical staining of PTTG-1. (A + B) positive control of germ cells in testis; (C) negative control of uropoietic tubuli 
stroma cells and globuli of the kidney; SCLC with negative PTTG-1 expression (D); low PTTG-1 expression (E) and strong 
PTTG-1 expression (F). Adenocarcinoma (NSCLC) with negative PTTG-1 expression (G), low PTTG-1 expression (H) and 
strong PTTG-1 expression (I). Squamous cell carcinoma (NSCLC) with low PTTG-1 expression (J) and strong PTTG-1 
expression (K). (L), note the positive cytoplasmatic staining of normal bronchial epithelium.
A C
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uniform within the biopsies. For those few cases with a
difference in staining intensity, the strongest intensity was
chosen for the assessment of PTTG-1. The proportion of
positive cells was determined semiquantitatively: (I)
none, (II) between 1% and 50%, (III) between 51% and
75%, and (IV) more than 75% of the tumor cells with
PTTG-1 expression. The percentage of positive cells was
estimated in agreement with all three observers.
Statistical methods
Immunohistochemical staining was performed without
prior knowledge of clinical parameters. Mean and stand-
ard error are reported for several clinical parameters. The
Kaplan-Meier survival analysis with log rank test was used
to compare clinical parameters with PTTG-1 expression.
Two sided t-test was performed to compare clinical varia-
bles of PTTG-1 positive, PTTG-1 low positive and PTTG-1
negative group. For multivariate analysis, a Cox regression
model with a forward stepwise selection was used. The
following variables were included for multivariate analy-
sis: gender (male versus female), age (≤ 60 versus > 60
years), performance status (classified into WHO 0 vs. I vs.
II vs. III), tumor stage (WHO classification), metastasis
(no metastasis vs. metastasis), hemoglobin level (< 12
versus  ≥ 12 mg/dl), platelet count (< 150.000/µl,
150.000–400.000 µl, > 400.000 µl), LDH level (classified
into serum levels ≤ 240 versus > 240 units/L), leucocyte
count (≤ 11.000/µl versus >11.000/µl) as well as staining
intensitiy of PTTG-1 expression (PTTG-1 negative/ low
versus PTTG-1 strong) and quantitative PTTG-1 expres-
sion (PTTG-1 expressing tumor cell proportion of ≤ 50%
versus > 50%). Pearson's bivariant correlation was per-
formed to evaluate a correlation between PTTG-1 expres-
3A and 3B Association of PTTG-1 expression and survival  in SCLC tumors Figure 3
3A and 3B Association of PTTG-1 expression and survival in 
SCLC tumors. (A): no statistical differences in survival time 
between patients with SCLC of no, low or strong PTTG-1 
expression were seen (p = 0.0843). (B): a statistical significant 
difference on survival time was observed (p = 0.0291), when 
comparing those patients with PTTG-1 negative/low expres-
sion (grey line) with those patients with strong PTTG-1 
expression (black line). PTTG-1 strong expressing cases 
(black line) had a statistical longer mean survival time of 379 
± 66 days compared with 265 ± 18 days for those patients 
with no/low PTTG-1 expression (grey line).
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Proportion of PTTG-1 positive tumor cells and PTTG-1  staining intensities of SCLC (N = 136); white bar represents  PTTG-1 negative cases; light grey and black bars represent  PTTG-1 low and strongly stained SCLC tumors, respectively Figure 2
Proportion of PTTG-1 positive tumor cells and PTTG-1 
staining intensities of SCLC (N = 136); white bar represents 
PTTG-1 negative cases; light grey and black bars represent 
PTTG-1 low and strongly stained SCLC tumors, respectively.
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sion or proportion of PTTG-1-expressing cells to clinical
parameters. Statistical analysis was performed using SPSS
software 12.0. Significance is defined as p < 0.05 and the
respective values are given in the text.
Results
Immunostaining of PTTG-1 in tumors from patients with 
SCLC
PTTG-1 expression was observed in 87 of 136 examined
tumors (64%). With regard to the degree of expression
low cytoplasmatic staining intensity was found in 60 cases
(44.1%) and strong cytoplasmatic staining intensity was
found in 27 cases (19.9%), respectively. There was no
PTTG-1 expression in 49 (36%) cases (Figure 1).
Positive tumors mostly showed more than 75% of stained
cells (64/136; 47.1%). Proportion of PTTG-1 positive cells
between 1% and 50%, and between 51% and 75% were
found in 7 (5.1%) and 16 (11.8%) of all tumors, respec-
tively, whereas 49 (36%) were PTTG-1 negative (Figure 2).
Prognostic value of PTTG-1 in patients with SCLC using 
Kaplan-Meier survival curves
Median and mean survival rates for all 136 patients with
SCLC were 255 ± 16 days and 287 ± 20 days. One year and
five year survival rates were 26.9% and 0%, respectively.
To evaluate the relationship of different PTTG-1 intensi-
ties on survival, the survival curves of the three groups
showing no, low or strong PTTG-1 staining intensities
were compared. Differential expression of PTTG-1 was not
associated with survival up to 300 days (p = 0.0843; Fig-
ure 3A). Of notice, beyond 300 days, a significant
improved survival rate was observed for those patients
with strong PTTG-1 expression compared to those with no
or low PTTG-1 expression. No significant difference was
observed between the survival curves of patients with no
or low PTTG-1 staining (mean survival: 249 ± 20 days ver-
sus 278 ± 29 days, p = 0.7026). Therefore, PTTG-1 nega-
tive or low stained cases were grouped together for further
analysis.
Patients with negative or low expression of PTTG-1 had a
significant (p = 0.0291) shorter mean survival of 265 ± 18
days compared with 379 ± 66 days for those patients with
strong PTTG-1 expression (Figure 3B). No significant dif-
ference was observed between the two groups (PTTG-1-
negative/low vs. PTTG-1 strong) with respect to gender,
age, smoking status, performance status, tumor stage,
mean cycles of chemotherapy, radiotherapy, mean hemo-
globin level, mean platelet count, mean leukocyte count
and mean lactate dehydrogenase using two sided t-test.
Next, the proportion of PTTG-1 expression was correlated
to survival of the SCLC patients. In order to evaluate the
proportion of PTTG-1 expression in SCLC: tumors with ≤
50% PTTG-1 expression (including negative cases) and
tumors with > 50% of PTTG-1 expression were compared.
A trend to significance in mean survival of 241 ± 18 days
(PTTG-1 expression ≤ 50%) versus 319 ± 31 days (PTTG-
1 expression > 50%) was observed for the two groups (p =
0.0541). Both groups did not show statistical differences
with respect to other clinical parameters.
Clinical parameters and PTTG-1 expression in 
multivariate analysis for patients with SCLC
Next to PTTG-1 status, other clinical parameters such as
performance status (WHO 0/I vs. II/III; p= 0.0007), tumor
stage (I/II vs. III/IV; p = 0.0117) and LDH level (serum lev-
els ≤ 240 units/l vs. > 240 units/l; p = 0.0246) were also
related to survival time using Kaplan-Meier analysis.
According to Pearson's bivariant correlation analysis
PTTG-1 expression was not correlated to any other clinical
variable. In order to test PTTG-1 as an independent prog-
nostic factor, multivariate anaysis was performed. As a
result, the staining intensity of PTTG-1 expression (p =
0.047), tumor stage (p = 0,051), performance status (p =
0.015), LDH level (p = 0.001) and hemoglobin level (p=
0.011) were identified as independent prognostic param-
eters by the Cox regression modell (Table 3). In contrast,
the percentage of PTTG-1 positive tumor cells, thrombo-
cyte count, leucocyte count, gender and age were irrele-
vant with regard to survival time (p > 0.2).
Immunostaining of PTTG-1 in tumors from patients with 
NSCLC
PTTG-1 expression was observed in 89 of 91 examined
tumors (97.8%). With regard to the degree of PTTG-1
expression low PTTG-1 staining intensity was found in 52
cases (57.1%) and strong cytoplasmatic PTTG-1 staining
intensity was found in 37 cases (40.7%). There was no
PTTG-1 expression in 2 (2.2%) cases (Figure 1).
Table 3: Variables accepted in the forward selection model of the 
Cox regression as explanatory factors in SCLC patients
p-value
Staining intensity of tumor cells expressing PTTG-1a 0.047
Stageb 0.051
Performance statusc 0.015
LDHd 0.001
Hemoglobine 0.011
a-negative/low PTTG-1 expressing tumor cells vs. PTTG-1 strong 
expressing tumor cells;
b-according to TNM-system: stage I/II vs. III/IV;
c-performance status according to WHO 0 vs. I vs. II vs. III;
d-LDH serum levels ≤ 240 units/l vs. > 240 units/l;
e-hemoglobin levels ≤ 12 g/dl vs. >12 g/dlJournal of Carcinogenesis 2006, 5:4 http://www.carcinogenesis.com/content/5/1/4
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Positive tumors mostly showed more than 75% of stained
cells (68/91; 74.7%). Proportions of PTTG-1 positive
tumor cells between 1% and 50%, between 51% and 75%
were found in 6 (6.6%) and 15 (16.5%) of all tumors,
respectively, only 2 (2.2%) cases were PTTG-1 negative
(Figure 4).
Prognostic value of PTTG-1 in patients with NSCLC using 
Kaplan-Meier survival curves
Median and mean survival rates for all 91 patients with
NSCLC were found to be 401 ± 41 days and 325 ± 56 days.
Patients with NSCLC had one year and five year survival
rates of 46.6% and 1.2%, respectively.
No significant difference between median and mean sur-
vival was observed for tumors from patients with no or
low PTTG-1 expression (p = 0.3063). Consequently, neg-
ative and low stained cases were grouped together. As a
result PTTG-1 expression was negatively correlated with
survival. Patients with strong PTTG-1 expression had an
unfavourable prognosis showing a mean survival of 306 ±
58 days compared with patients with PTTG-1 low or
PTTG-1 negative stainings with a mean survival of 463 ±
55 days (p = 0.0386; Figure 5A).
In order to exclude a possible bias due to different thera-
pies, surgically resected patients, who had a significant
better overall survival than unresected patients (p =
0.0001), were removed from the analysis. Looking at the
subgroup of patients in stage IIIB and IV (n = 76) receiving
palliative chemotherapy, a significant difference on sur-
vival (p = 0.0229) with regard to PTTG-1 expression was
observed again (Figure 5B).
5A and 5B Association of PTTG-1 expression and survival  in NSCLC tumors Figure 5
5A and 5B Association of PTTG-1 expression and survival in 
NSCLC tumors. (A): statistical difference in survival time 
between patients with NSCLC (n = 91) of no/low PTTG-1 
expression (black line) and strong PTTG-1 expression (grey 
line) was seen. Patients with strong PTTG-1 expression had a 
significant (p = 0.0386) shorter survival time. (B): looking at 
PTTG-1 expression for the subgroup of patients with 
advanced NSCLC receiving palliative chemotherapy (n = 76), 
a statistically significant difference on survival time between 
PTTG-1 no/low expressing group (black line) and PTTG-1 
strong expressing group (grey line) was observed (p = 
0.0229).
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Proportion of PTTG-1 positive tumor cells and PTTG-1  staining intensities of NSCLC (N = 91); white bar represents  PTTG-1 negative cases; light grey and black bars represent  PTTG-1 low and strongly stained NSCLC tumors, respec- tively Figure 4
Proportion of PTTG-1 positive tumor cells and PTTG-1 
staining intensities of NSCLC (N = 91); white bar represents 
PTTG-1 negative cases; light grey and black bars represent 
PTTG-1 low and strongly stained NSCLC tumors, respec-
tively.
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In order to evaluate a possible correlation of clinical vari-
ables to PTTG-1 expression, the two sided t-test was used.
When comparing patients group with strong PTTG-1
expression versus negative/low PTTG-1 expression statisti-
cally significant differences were noticed with respect to
gender (p = 0.04), LDH level (p = 0.005), leucocyte count
(p = 0.016) and tumor stage (p = 0.021). Using Pearson's
bivariant correlation analysis (p < 0.05) a strong expres-
sion of PTTG-1 was associated with advanced LDH level,
lymphnode involvement and distant metastases. In con-
trast, no correlation with PTTG-1 expression was found
for the following clinical variables: age, smoking status,
performance status, mean cycles of chemotherapy, radio-
therapy, erythropoetin substitution, mean hemoglobin
level and mean platelet count.
Clinical parameters and PTTG-1 expression in 
multivariate analysis in patients with NSCLC
Among the clinical parameters, performance status (WHO
0 vs. I vs. II), LDH (serum levels ≤ 240 units/l vs. > 240
units/l), leucocyte count (< 11.000/nl vs. ≥ 11.000/nl)
and TNM classification (stage I vs. II vs. II vs. IV) were also
related to survival time using Kaplan-Meier analysis for
NSCLC (data not shown). According to Pearson's bivari-
ant correlation analysis PTTG-1 expression was correlated
to increased LDH level (p < 0.01) and leucocyte count (p
< 0.05), extended lymph node involvement (p < 0.05)
and distant metastases (p < 0.01). To examine the influ-
ence of PTTG-1 expression as an independent prognostic
factor for unresectable NSCLC patients multivariate anal-
ysis was performed. As a result, only PTTG-1 staining
intensity (p = 0.025), tumor stage (p = 0.044) and per-
formance status (p = 0.016) were identified as independ-
ent prognostic parameters by the Cox regression model
(Table 4). In contrast, gender, age, hemoglobin level,
thrombocyte count, leucocyte count, LDH level and pro-
portion of PTTG-1 expression were irrelevant with regard
to survival time (p > 0.05).
Discussion
In this study a high prevalence of PTTG-1 expression in
lung cancer was seen. We showed that 64% of SCLC
tumors and 97.8% of NSCLC tumors examined by immu-
nohistochemistry were positive for PTTG-1 expression. To
our knowledge, only a few reports refer to the presence of
PTTG-1 in lung cancer. In line with our results a PTTG-1
expression was observed in 9 out of 10 primary adenocar-
cinomas of the lung using immunohistochemial methods
[17]. Performing RT-PCR for the detection of PTTG-1
mRNA Honda et al. detected PTTG-1 expression in 12 out
of 14 NSCLCs. Interestingly, squamous cell carcinomas
had a tendency to express more PTTG mRNA than adeno-
carcinomas [18].
Next, the prognostic relevance of PTTG-1 expression on
survival of the patients was examined. A strong PTTG-1
expression was significantly associated with favourable
prognosis for patients with SCLC prolonging the mean
survival for 3.5 months. In contrast, patients with NSCLC
showing strong PTTG-1 tumor expression had a rather
unfavourable overall survival which was 5.2 months
lower than the group of patients with negative or low
PTTG-1 expression. At first glance our results seem to be
contradictory but might be a reflection of the varying role
of PTTG-1 in the pathophysiology of the different histo-
logical subtypes of lung cancer. This view is not entirely
hypothetical when looking at the literature. On one hand,
recent studies indicate that overexpression of PTTG-1 was
associated to induce p53 independent and p53-depend-
ent apoptosis [13,19] when looking at breast cancer cells
or kidney cell lines. Further, PTTG-1 overexpression in the
human lung cancer cell line A549 inhibited the cell
growth via activation of p21 [20]. In contrast to these
results, others suggest that PTTG-1 expression led to an
increased rate of cell growth or inhibition of apoptosis.
For example, p53 mediated cell death of NSCLC lung can-
cer cell line H1299 was impeded by PTTG-1 expression by
blocking the specific binding of p53 to DNA and inhibit-
ing the transcriptional function of p53 [14]. In cervix car-
cinoma cells inhibition of PTTG-1 using antisense-ODNs
leads to growth inhibition and increased apoptosis [21].
Further, several other studies implicate that PTTG-1 over-
expression was associated to chromosomal instability,
increased distant metastases, increased neoangiogenesis
and invasiveness of the tumor [5,6,22]. These features,
induced by PTTG-1 overexpression, would rather cause a
more aggressive tumor phenotype. This would be in line
with our results showing that increased PTTG-1 expres-
sion was significantly correlated to clinical and patholog-
ical markers indicating an unfavourable outcome for
patients with NSCLC such as extensive lymph node
metastases, presence of distant metastases and increased
LDH levels. Differences in PTTG-1 expression levels could
be translated in a mean survival difference of 5.2 months
in the NSCLC patient subgroups which was statistically
significant in univariate and multivariate analysis. As a
result, PTTG-1 meets the requirements to serve as a
Table 4: Variables accepted in the forward selection model of the 
Cox regression as explanatory factors in NSCLC patients
p-value
Staining intensity of tumor cells expressing PTTG-1a 0.025
Stageb 0.044
Performance statusc 0.016
a-negative/low PTTG-1 expressing tumor cells vs. PTTG-1 strong 
expressing tumor cells;
b-according to TNM-system: stage I-III vs. IV;
c-performance status according to WHO 0 vs. I vs. IIJournal of Carcinogenesis 2006, 5:4 http://www.carcinogenesis.com/content/5/1/4
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biomarker in patients with NSCLCs. In this context a pre-
dictive marker like PTTG-1 might be valuable to come to
a decision on the still controversially discussed question if
a patient with stage I-IIIA NSCLC should be treated with
adjuvant chemotherapy or radiation after a histologically
confirmed R0-resection of the tumor.
In conclusion, the functions of PTTG-1 are complex and
antithetic and might differ from tumor cell to tumor cell.
This is examplified at its best by our results showing an
association between PTTG-1 expression and overall sur-
vival of tumor patients in dependence of lung cancer sub-
type. We found that a strong expression of PTTG-1 in
SCLC was associated with a significant improved outcome
for patients. In contrast, a strong expression of PTTG-1 in
patients with NSCLC was associated with a significant
shorter survival, advanced lymph node metastases and
distant metastases. These results underline that a high
expression of PTTG-1 plays an important role in biology
of lung cancer, which differs in SCLC and NSCLC. Further
experiments are needed to understand the different path-
ways of PTTG-1 in different lung cancer subtypes.
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